The management of secondary osteoporosis

Best Practice and Research: Clinical Rheumatology

Volumn 19, Issue 6, 2005, Pages 1021-1037

  Kelman, Ariella ^a   Lane, Nancy E ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen deprivation therapy; Ankylosing spondylitis; Aromatase inhibitors; Glucocorticoids; Lupus; Osteomalacia; Osteonecrosis; Rheumatoid arthritis; Secondary osteoporosis; Vitamin D deficiency

Indexed keywords

ANASTROZOLE; ANTIANDROGEN; ANTICONVULSIVE AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN A; CYPROTERONE ACETATE; ERGOCALCIFEROL; ESTRADIOL; ESTROGEN; FLUTAMIDE; GLUCOCORTICOID; GONADORELIN AGONIST; HEPARIN; LETROZOLE; METHOTREXATE; NERIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RISEDRONIC ACID; TACROLIMUS; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ANKYLOSING SPONDYLITIS; BONE DENSITY; BONE MASS; BONE MINERAL; BONE NECROSIS; BREAST CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; FRACTURE; HOT FLUSH; HUMAN; MEDICAL ASSESSMENT; NONHUMAN; ORTHOPEDIC SURGERY; OSTEOLYSIS; OSTEOMALACIA; PATHOPHYSIOLOGY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SECONDARY OSTEOPOROSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; VITAMIN D DEFICIENCY;

ANDROGEN ANTAGONISTS; AROMATASE INHIBITORS; ARTHRITIS; BONE DENSITY; FRACTURES, BONE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEDICAL HISTORY TAKING; OSTEOMALACIA; OSTEOPOROSIS; PHYSICAL EXAMINATION; RISK FACTORS; SPONDYLITIS, ANKYLOSING; VITAMIN D DEFICIENCY;

EID: 28644451831     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2005.06.005     Document Type: Review

References (78)

1. E. Stein & E. Shane Secondary osteoporosis Endocrinology and Metabolism Clinics of North America 1 2003 115-134
2. S.F. Hodgson N.B. Watts J.P. Bilezikian et al. American association of clinical endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003 Endocrine Practice 9 2003 544-564
3. C. Tannenbaum J. Clark K. Schwartzman et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women Journal of Clinical Endocrinology and Metabolism 10 2002 4431-4437
4. H.A. Bischoff H.B. Stahelin W. Dick et al. Effects of vitamin D and calcium supplementation on falls: A randomized controlled trial Journal of Bone and Mineral Research 18 2003 343-351
5. H.A. Bischoff H.B. Stahelin N. Urscheler et al. Muscle strength in the elderly: Its relation to vitamin D metabolites Archives of Physical Medicine and Rehabilitation 80 1999 54-58
6. M.D. Thomas D.M. Lloyd-Jones R.I. Thadhani et al. Hypovitaminosis D in medical inpatients The New England Journal of Medicine 338 1998 777-783
7. J.S. Adams V. Kantorovich C. Wu et al. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density Journal of Clinical Endocrinology and Metabolism 84 1999 2729-2730
8. G. Passeri G. Pini L. Troiano et al. Low vitamin D status, high bone turnover, and bone fractures in centarians Journal of Clinical Endocrinology and Metabolism 88 2003 5109-5115
9. N.E. Lane & M.S. Leboff Metabolic bone disease In E.D. Harris R.C. Budd & M.C. Genovese (eds.), Kelley's Textbook of Rheumatology 7th edn 2005 WB Saunders St Louis 1473-1492
10. G.R. Smith P.O. Collinson & P.D. Kiely Diagnosing hypovitaminosis D: serum measurements of calcium, phosphate, and alkaline phosphatase are unreliable, even in the presence of secondary hyperparathyroidism The Journal of Rheumatology 32 2005 684-689
11. L.A. Merlino J. Curtis T.R. Mikuls et al. Vitamin D intake is inversely associated with rheumatoid arthritis. Results from the Iowa Women's Health Study Arthritis and Rheumatism 50 2004 72-77
12. R.W. Chesney A. Hamstra et al. Reduced serum 1,25-(OH)2 vitamin D3 levels in prednisolone-treated adolescents with systemic lupus erythematosus Acta Paediatrica Scandinavica 68 1979 109-111
13. K. Muller N.J. Kriegbaum B. Baslund et al. Vitamin D3 metabolism in patients with rheumatic diseases: Low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus Clinical Rheumatology 14 1995 397-400
14. T.C. Barnes & R.C. Bucknall Vitamin D deficiency in a patient with systemic lupus erythematosus Rheumatology 43 2004 393-394
15. O. Sharma Hypercalcemia in granulomatous disorders: A clinical review Current Opinion in Pulmonary Medicine 6 2000 442-447
16. D.P. Trivedi R. Doll & K.T. Khaw Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial British Medical Journal 326 2003 469
17. R.P. Heaney Functional indices of vitamin D status and ramifications of vitamin D deficiency The American Journal of Clinical Nutrition 80 supplement 2004 1706S-1709S
18. D. Lyman Undiagnosed vitamin D deficiency in the hospitalized patient American Family Physician 71 2005 299-304
19. N. Binkley D. Krueger C.S. Cowgill et al. Assay variation confounds the diagnosis of hypovitaminosis D: A call for standardization Journal of Clinical Endocrinology and Metabolism 89 2004 3152-3157
20. H. Glerup K. Mikkelsen L. Poulsen et al. Commonly recommended daily intake of vitamin D is not sufficient if sunlight exposure is limited Journal of Internal Medicine 247 2000 260-268
21. N.E. Lane An update on glucocorticoid-induced osteoporosis Rheumatic Diseases Clinics of North America 27 2001 235-253
22. R.S. Weinstein R.L. Jilka A.M. Parfitt & S.C. Manolagas Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids - potential mechanisms of their deleterious effects on bone The Journal of Clinical Investigation 102 1998 274-282
23. H.G.M. Leufgens & C. Cooper The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis Osteoporosis International 13 2002 777-787
24. K.G. Saag R. Emkey T.J. Schnitzer et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis The New England Journal of Medicine 339 1998 292-299
25. D.M. Reid R.A. Hughes R.F. Laan et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European corticosteroid-induced osteoporosis treatment study Journal of Bone and Mineral Research 15 2000 1006-1013
26. Q. Rehman T.F. Lang C.D. Arnaud et al. Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in post-menopausal women with glucocorticoid-induced osteoporosis Osteoporosis International 14 2003 77-81
27. N.E. Lane S. Sanchez G.W. Modin et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial Journal of Bone and Mineral Research 15 2000 944-951
28. R.E. Orstavik G. Haugeberg T. Uhlig et al. Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables Annals of the Rheumatic Diseases 63 2004 177-182
29. R. Ramsey-Goldman J.E. Dunn C.F. Huang et al. Frequency of fractures in women with systemic lupus erythematosus: Comparison with United States population data Arthritis and Rheumatism 42 1999 882-890
30. N.C. Walsh & E.M. Gravallese Bone loss in inflammatory arthritis: mechanisms and treatment strategies Current Opinion in Rheumatology 16 2004 419-427
31. C.T. Ritchlin S.A. Haas-Smith P. Li et al. Mechanisms of TNF-α and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis The Journal of Clinical Investigation 111 2003 821-831
32. T. Suda N. Takahadhi N. Udagawa et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families Endocrine Reviews 20 1999 345-357
33. E. Jimi I. Nakamura L.T. Duong et al. Interleukin -1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells Experimental Cell Research 247 1999 84-93
34. J. Zwerina S. Hayer M. Tohidast-Akrad et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction Arthritis and Rheumatism 50 2004 277-290
35. G. Schett K. Redlich S. Hayer et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice Arthritis and Rheumatism 48 2003 2042-2051
36. R. Bessant & A. Keat How should clinicians manage osteoporosis in ankylosing spondylitis? The Journal of Rheumatology 7 2002 1511-1519
37. D.M. Reid J.J. Nicoll N.S. Kennedy et al. Bone mass in ankylosing spondylitis The Journal of Rheumatology 13 1986 932-935
38. C. Cooper L. Carbone C. Michet et al. Fracture risk in patients with ankylosing spondylitis - a population-based study The Journal of Rheumatology 21 1994 1877-1882
39. A. Calin Osteoporosis and ankylosing spondylitis British Journal of Rheumatology 30 1991 318-319
40. D. Mitra D.M. Elvins D.J. Speden & A.J. Collins The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density Rheumatology 39 2000 85-89
41. H. Franck T. Meurer & L.C. Hofbauer Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin levels in patients with ankylosing spondylitis The Journal of Rheumatology 31 2004 2236-2241
42. S.H. Ralston G.D.K. Urquhart M. Brzeski & R.D. Sturrock Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis British Medical Journal 300 1990 563-565
43. Y. Jiang H.K. Genant I. Watt et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores Arthritis and Rheumatism 43 2000 1001-1009
44. V. Strand & J.T. Sharp Radiographic data from recent randomized controlled trials in rheumatoid arthritis: What have we learned? Arthritis and Rheumatism 48 2003 21-34
45. W.P. Maksymowych G.S. Jhangri A.A. Fitzgerald et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis Arthritis and Rheumatism 46 2002 766-773
46. M.C. Lodder & P.A. Van Pelt Effects of high dose intravenous pamidronate on disease activity and bone metabolism in patients with active rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial The Journal of Rheumatology 30 2003 2080-2081
47. C.S. Yee N. Crabtree J. Skan et al. Prevalence and predictors of fragility fractures in systemic lupus erythematosus Annals of the Rheumatic Diseases 64 2005 111-113
48. T.P. Van Staa R.F. Laan I.P. Barton et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy Arthritis and Rheumatism 48 2003 3224-3229
49. E.L. Dubois & L. Cozen Avascular bone necrosis associated with systemic lupus erythematosus The Journal of the American Medical Association 174 1960 966-971
50. M. Abu-Shakra D. Buskila & Y. Shoenfeld Osteonecrosis in patients with SLE Clinical Reviews in Allergy & Immunology 25 2003 13-24
51. S.N. Oh W.H. Jee S.M. Cho et al. Osteonecrosis in patients with systemic lupus erythematosus: MR imaging and scintigraphic evaluation Clinical Imaging 28 2004 305-309
52. D.D. Gladman V. Chaudhry-Ahluwalia E. Bogoch & M.B. Urowitz Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus The Journal of Rheumatology 28 2001 2226-2229
53. W.F. Marcus R.A. Enneking & R.A. Massam The silent hip in idiopathic aseptic necrosis. Treatment by bone-grafting The Journal of Bone and Joint Surgery American 55 1973 1351-1366
54. M.H. Huo E.A. Salvati M.G. Browne et al. Primary total hip arthroplasty in systemic lupus erythematosus The Journal of Arthroplasty 7 1992 51-56
55. M.A. Mont A.C. Fairbank M. Petri & D.S. Hungerford Core decompression for osteonecrosis of the femoral head in systemic lupus erythematosus Clinical Orthopaedics and Related Research 334 1997 91-97
56. R.T. Greenlee M.B. Hill-Hapmon T. Murray & M. Thun Cancer statistics Cancer Journal for Clinicians 51 2001 15-36
57. G.W. Chodak T. Keane & L. Klotz Critical evaluation of hormonal therapy for carcinoma of the prostate Urology 60 2002 201-208
58. M. Bolla L. Collette L. Blank et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial Lancet 360 2002 103-108
59. V.B. Shaninian Y. Kuo J.L. Freeman & J.S. Goodwin Risk of fracture after androgen deprivation for prostate cancer The New England Journal of Medicine 352 2005 154-164
60. M.R. Cooperberg G.D. Grossfeld D.P. Lubeck & P.R. Carroll National practice patterns and time trends in androgen ablation for localized prostate cancer Journal of the National Cancer Institute 95 2003 981-989
61. D. Mittan S. Lee E. Miller et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs Journal of Clinical Endocrinology and Metabolism 87 2002 3656-3661
62. H.W. Daniell S.R. Dunn D.W. Ferguson et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer The Journal of Urology 163 2000 181-186
63. T.L. Krupski M.R. Smith W. Chan Lee et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy Cancer 101 2004 541-549
64. M.R. Smith J. Eastham D.M. Gleason et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer The Journal of Urology 169 2003 2008-2012
65. N. Morabito A. Gaudio A. Lasco et al. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer Journal of Bone and Mineral Research 19 2004 1766-1770
66. J.L. Ockrim E.N. Lalani L.M. Banks et al. Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer The Journal of Urology 172 2004 2203-2207
67. TH Diamond CS Hiagno MR Smith et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies Cancer 100 2004 892-899
68. American Cancer Society Cancer Facts and Figures 2004 2004 American Cancer Society Atlanta
69. J.R. Mackey & A.A. Joy Skeletal health in postmenopausal survivors of early breast cancer International Journal of Cancer 10 2005 1010-1015
70. B.S. Hulka Epidemiology of susceptibility to breast cancer Progress in Clinical and Biological Research 395 1996 159-174
71. B. Fisher J.P. Constantino D.L. Wickerham et al. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study Journal of the National Cancer Institute 90 1998 1371-1388
72. J. Cuzick First results from the International Breast Cancer Intervention Study (IBIS-1): A randomized prevention trial Lancet 360 2002 817-824
73. ATAC Trialists Group Results of the ATAC (Arimidex, Tamoxifen, Alone, or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60-62
74. J. Geisler P.E. Lonning L.E. Krag et al. Estrogens and bone metabolism in postmenopausal women with early breast cancer at low risk treated with exemestane: A randomized placebo-controlled study Proceedings of the American Society of Clinical Oncology 23 2004 9
75. R.C. Coombes E. Hall L.J. Gibson R. Paridaens et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with breast cancer The New England Journal of Medicine 350 2004 1081-1092
76. M. Gnant H. Hausmaninger H. Samonigg et al. Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (±zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: Results of a randomized multicenter trial Breast Cancer Research and Treatment 76 supplement 1 2002 S31
77. T.J. Powles E. McCloskey A.H. Paterson et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer Journal of the National Cancer Institute 90 1998 704-708
78. T. Saarto C. Blomqvist M. Valimaki et al. Chemical castration by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients Journal of Clinical Oncology 15 1997 1341-1347